GLP1 Receptor Agonist Therapy with and without SGLT2 inhibitors in Patients with Type 2 Diabetes

Introduction

The Effect of GLP1 Receptor Aagonist on Cardiovascular Death, Myocardial Infarction or Stroke

The Effects of GLT2 Inhibitors on Cardiovascular Events

The Role of SGLT2 Inhibitors in Cardiometabolic Protection in the Broader Type to Diabetes Population